Cellectar Biosciences (CLRB) Prepaid Assets (2010 - 2026)
Cellectar Biosciences (CLRB) posted Prepaid Assets of $842432.0 for Q4 2025, down 21.08% sequentially from $1.1 million in Q3 2025, and down 12.4% YoY from $961665.0 in Q4 2024.
Cellectar Biosciences (CLRB) Prepaid Assets (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Prepaid Assets for 16 years, with the latest figure at $842432.0 in Q4 2025.
- Quarterly Prepaid Assets fell 12.4% year-over-year to $842432.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $842432.0 (down 12.4% YoY) and the FY2025 annual result came in at $842432.0, down 12.4% from the prior year.
- Prepaid Assets slipped to $842432.0 in Q4 2025 per CLRB's latest filing, from $1.1 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $2.0 million in Q2 2024 and troughed at $347028.0 in Q2 2021.
- A 5-year average of $999695.0 and a median of $968800.5 in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2021 and 2024: Prepaid Assets slumped 41.54% in 2021, then surged 345.93% in 2024.
- Over 5 years, Prepaid Assets stood at $867485.0 in 2021, then decreased by 23.54% to $663243.0 in 2022, then jumped by 33.92% to $888225.0 in 2023, then climbed by 8.27% to $961665.0 in 2024, then declined by 12.4% to $842432.0 in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $842432.0, $1.1 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 883,659.00 |
| Dec 31, 2025 | 842,432.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 987,495.00 |
| Dec 31, 2024 | 961,665.00 |
| Sep 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 2.04 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 888,225.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 456,679.00 |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 663,243.00 |
| Sep 30, 2022 | 975,936.00 |
| Jun 30, 2022 | 479,668.00 |
| Mar 31, 2022 | 760,420.00 |
| Dec 31, 2021 | 867,485.00 |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 347,028.00 |